InterShunt

Executive Summary

InterShunt is an early-stage medical device company developing a novel percutaneous atrial shunt system for heart failure. Unlike existing shunts that require permanent implants, InterShunt's Percutaneous Atrial Shunt Catheter System (PAS-C) creates a temporary interatrial shunt to reduce left atrial pressure without leaving any device behind. This unique approach aims to relieve symptoms of heart failure while avoiding long-term complications associated with permanent implants, such as thrombosis or erosion. The company was founded in 2020 and is based in San Francisco, focusing on the large and growing heart failure market. InterShunt's technology has the potential to address a significant unmet need, as heart failure affects millions of patients worldwide and current treatment options are limited. The minimally invasive nature of the procedure could offer a safer alternative to surgical shunts and be more acceptable to patients and physicians. However, as a private company with no disclosed funding or clinical data, InterShunt is at a very early development stage. The company must demonstrate safety and efficacy in clinical trials, secure regulatory approvals, and navigate competitive pressures from other shunt technologies and heart failure devices. While the concept is promising, the high technical and regulatory risks warrant a cautious outlook.

Upcoming Catalysts (preview)

• Q3 2027First-in-human clinical data readout30% success
• Q4 2026Series A financing round40% success
• Q2 2027FDA Breakthrough Device designation50% success